布地奈德对哮喘有多大效果？

It is clinically used in patients with glucocorticoid-dependent or independent bronchial asthma and asthmatic chronic bronchitis. How effective is budesonide on asthma? Clinical trials analyzed the efficacy of seretide and budesonide in the treatment of bronchial asthma.

The trial treated 140 adult patients with asthma. The patients were randomly divided into an observation group and a control group, with 70 cases in each group. The control group inhaled Pulmicol (budesonide dry powder) 4 inhalations/time, 2 times/d. The observation group inhaled Seretide 1 inhalation/time, 2 times/d on the basis of the control group. Both groups were treated continuously for 6 weeks. The test results showed that after treatment, the differences in FEV1, FVC, FEV1/FVC, and PEF between the two groups of patients were statistically significant (P less than 0.05); the total effective rate of the observation group was 94.3%. The total effective rate in the control group was 74.3%, and the difference between the two groups was statistically significant (P less than 0.05). The conclusion of the trial shows that treatment with seretide combined with budesonide is more effective than budesonide alone.

Budesonide is currently one of the most commonly used drugs to treat asthma in countries around the world. Budesonide has a strong local anti-inflammatory effect, and its mechanism may be: enhancing the stability of mast cells and lysosomal membranes, reducing degranulation and the release of lysosomal enzymes; anti-immune effects, inhibiting inflammation caused by immune responses, etc.; for patients with airway hyperresponsiveness, this product can significantly reduce the airway response to histamine and methacholine. About 10% of the aerosol is deposited in the lung tissue after inhalation. About 90% of the swallowed residual drugs are rapidly metabolized by the liver and inactivated.

(Budesonide) is a light beige solid chemical substance. In clinical studies, no increase in the incidence of adverse reactions was seen when budesonide was given together with other commonly used drugs for the treatment of asthma. Ketoconazole, a potent inhibitor of cytochrome P450 3A, can increase the plasma concentration of budesonide and should be monitored clinically.